NEW from BBI Solutions, D-dimer antibodies sold under license of performance proven hybridoma cell lines from bioMérieux, and manufactured under cGMP conditions at BBI’s Maine facility.
Customers can be confident in sampling this performance tested matched pair to D-dimer, a biomarker with broad clinical utility including assessment of acute myocardial infarction, pulmonary embolism, sepsis and disseminated intravascular coagulation. By manufacturing the antibodies in-house, BBI can ensure secure supply with increased batch-to-batch consistency and customise production timelines and parameters to meet customer validation needs.
Characterisation: A colorimetric sandwich ELISA demonstrating sensitive detection of human D-Dimer (P202-3). Data generated using three lots of each antibody demonstrating assay robustness and lot-to-lot reproducibility of the antibody productions.
Use in Assays
Clones P2C5A10 and P10B5E12C9 have been successfully used in commercialised bioMérieux immunoassay products*, in which P2C5A10 was the detector antibody and clone P10B5E12C9 was the capture antibody.
* VIDAS and/or VIKIA and/or BIONEXIA
A fluorescence immunoassay standard curve prepared using P2C5A10 as the detector antibody and P10B5E12C9 as the capture antibody in an optimised assay format showing quantitative detection of D-Dimer
Why choose BBI's D-Dimer Antibodies?
+ Antibody clones used as matched pair in commercialised bioMérieux assays – proven performance
+ Manufactured in- house at BBI for security of supply
+ cGMP production and quality management for increased batch-to-batch consistency